BI Asset Management Fondsmaeglerselskab A S Sells 12,283 Shares of IQVIA Holdings Inc. $IQV

BI Asset Management Fondsmaeglerselskab A S lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 55.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,036 shares of the medical research company’s stock after selling 12,283 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in IQVIA were worth $1,712,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Ameliora Wealth Management Ltd. bought a new stake in IQVIA in the fourth quarter valued at about $25,000. International Assets Investment Management LLC bought a new position in IQVIA during the fourth quarter worth about $27,000. Gilpin Wealth Management LLC acquired a new stake in IQVIA during the fourth quarter valued at approximately $27,000. CrossGen Wealth LLC bought a new stake in shares of IQVIA in the 4th quarter valued at approximately $28,000. Finally, Activest Wealth Management raised its holdings in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after buying an additional 118 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 8.5%

IQV opened at $185.76 on Thursday. The firm has a 50 day simple moving average of $173.95 and a 200 day simple moving average of $190.34. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The company has a market cap of $31.00 billion, a price-to-earnings ratio of 23.02, a price-to-earnings-growth ratio of 1.47 and a beta of 1.21. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period last year, the firm earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its board has initiated a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

IQV has been the topic of several recent analyst reports. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the company from $174.00 to $213.00 in a research note on Monday, March 9th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, June 14th. Royal Bank Of Canada initiated coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. HSBC set a $210.00 price target on IQVIA in a report on Wednesday, June 3rd. Finally, Evercore reiterated an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.